News >

Epoetin Alfa Biosimilar Launched in United States at Discounted Cost

Kristi Rosa
Published: Wednesday, Nov 14, 2018

John P. Kennedy

John P. Kennedy

Epoetin alfa-epbx (Retacrit), the biosimilar to epoetin alfa (Procrit/Epogen) has been launched in the United States at a significant discount, according to Pfizer, the developer of the injectable.1 The shipment of the biosimilar to wholesalers throughout the United States began on November 12, 2018.

Epoetin alfa-epbx has been granted 2 unique assigned Q codes from the Centers for Medicare and Medicaid Services: Q5105 for End-Stage Renal Disease (ESRD) and Q5106 for non-ESRD. Under the hospital outpatient prospective payment system, epoetin alfa-epbx qualifies for pass-through status.


  1. Pfizer. Pfizer introduced biosimilar Retacrit (epoetin alfa-epbx) injection in the US at a substantial discount. Published November 14, 2018.
  2. Pfizer. Pfizer’s biosimilar RETACRIT® (epoetin alfa-epbx) approved by U.S. FDA. Published May 15, 2018. Accessed November 14, 2018.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication